Kevin Tay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kevin Tay has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Miriam Tao
14 shared publicationsRichard Quek
13 shared publications- Soon Thye Lim
Director’s office, National Cancer Centre Singapore, Singapore, Singapore
13 shared publications - Soo-Yong Tan
Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
11 shared publications Anna Gan
10 shared publications- Bin Tean Teh
Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, Singapore 169857, Singapore
10 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Supplementary Table 1. Clinical characteristics of patients with MET rearrangement-positive tumors in the DFCI/GRCC clinicopathologic cohort. Supplementary Table 2. Clinical characteristics of patients with MET fusion-positive tumors in the SPARTA-II clinical trial, cohort D. Supplementary Table 3. Treatment history of patients with MET fusion-positive solid tumors in the SPARTA-II clinical trial, cohort D. Supplementary Table 4. Summary of treatment emergent adverse events (TEAEs) in the SPARTAII clinical trial, cohort D. Supplementary Table 5. Details of treatment emergent adverse events (TEAEs), ordered by decreasing frequency for all grades. Supplementary Table 6. Details of treatment-related treatment emergent adverse events (TEAEs), ordered by decreasing frequency for all grades.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Supplementary Table 1. Clinical characteristics of patients with MET rearrangement-positive tumors in the DFCI/GRCC clinicopathologic cohort. Supplementary Table 2. Clinical characteristics of patients with MET fusion-positive tumors in the SPARTA-II clinical trial, cohort D. Supplementary Table 3. Treatment history of patients with MET fusion-positive solid tumors in the SPARTA-II clinical trial, cohort D. Supplementary Table 4. Summary of treatment emergent adverse events (TEAEs) in the SPARTAII clinical trial, cohort D. Supplementary Table 5. Details of treatment emergent adverse events (TEAEs), ordered by decreasing frequency for all grades. Supplementary Table 6. Details of treatment-related treatment emergent adverse events (TEAEs), ordered by decreasing frequency for all grades.
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Supplementary Figure 1. Identification of MET rearrangement cases in the DFCI and GRCC cohorts. Supplementary Figure 2. Genomic features of MET rearrangements. Supplementary Figure 3. Oncoprint of likely oncogenic MET rearrangements and of unknown significance with select co-occurring genomic alterations that are generally recognized as common standalone mitogenic drivers. Supplementary Figure 4. Treatment and response to vebreltinib as per independent review committee (IRC) according to RECIST 1.1. Supplementary Figure 5. Clinical presentation of salivary gland tumor with ETV6::MET and in vitro modelling. Supplementary Figure 6. In vitro data of HLA-DRB1::MET Ba/F3 cells. Supplementary Figure 7. Sensitivity pattern of HLA-DRB1::MET WT and D1228V to MET TKIs. Supplementary Figure 8. Molecular dynamics simulation graphs. Supplementary Figure 9. Co-immunoprecipitation assay by HA.
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 from Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Supplementary Figure 1. Identification of MET rearrangement cases in the DFCI and GRCC cohorts. Supplementary Figure 2. Genomic features of MET rearrangements. Supplementary Figure 3. Oncoprint of likely oncogenic MET rearrangements and of unknown significance with select co-occurring genomic alterations that are generally recognized as common standalone mitogenic drivers. Supplementary Figure 4. Treatment and response to vebreltinib as per independent review committee (IRC) according to RECIST 1.1. Supplementary Figure 5. Clinical presentation of salivary gland tumor with ETV6::MET and in vitro modelling. Supplementary Figure 6. In vitro data of HLA-DRB1::MET Ba/F3 cells. Supplementary Figure 7. Sensitivity pattern of HLA-DRB1::MET WT and D1228V to MET TKIs. Supplementary Figure 8. Molecular dynamics simulation graphs. Supplementary Figure 9. Co-immunoprecipitation assay by HA.
- 10 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (6) , 1129-1140
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement–positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion–positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14–altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion–positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. Significance: MET rearrangement–positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.
- 10 April 2025
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (6) , 1129-1140
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements
Oncogenic translocations involving the MET gene have been reported in several cancer types, but detailed clinicogenomic characterization of these cancers is not well defined. In addition, prospective clinical trials evaluating the antitumor activity of MET inhibitors in MET rearrangement–positive cancers are limited. In this study, in a pan-cancer analysis of >46,000 solid tumors with comprehensive genomic profiling, we identified oncogenic MET rearrangements in ∼0.04% of cancers. Preliminary analysis from a phase II clinical trial of the type I MET tyrosine kinase inhibitor (TKI) vebreltinib in MET fusion–positive solid tumors demonstrated an objective response rate of 50% and disease control rate of 79%, with antitumor activity seen in diverse cancer types, including lung adenocarcinoma and intrahepatic cholangiocarcinoma, among others. Similar to MET exon 14–altered lung cancer, secondary mutations in the kinase domain can confer resistance to MET TKIs in MET fusion–positive cancers. Overall, these data categorize MET rearrangements as actionable targets in solid tumors. Significance: MET rearrangement–positive cancers are not well-characterized, and optimal treatment strategies are yet to be defined. Through comprehensive genomic analysis, preclinical modeling, and preliminary results of a phase II clinical trial, we demonstrate that MET fusions are a unique molecular subtype of cancers targetable with vebreltinib, a TKI in development.